Trials / Completed
CompletedNCT00533364
Effect of SBG in Patients With Breast Cancer
A Phase I/II Study to Assess the Effect of Soluble Beta-1,3/1,6-glucan in Combination With Standard Therapy in Patients With Breast Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Biotec Pharmacon ASA · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is set up to determine whether soluble beta-glucan (SBG) has * unfavourable side effects * beneficial treatment effects when given in combination with standard antibody and chemotherapy to patients with breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SBG (Soluble beta-glucan) | Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles. |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-08-01
- Completion
- 2010-01-01
- First posted
- 2007-09-21
- Last updated
- 2010-02-18
Locations
2 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT00533364. Inclusion in this directory is not an endorsement.